about
CYP2C19 polymorphism influences Helicobacter pylori eradication25 Years of Proton Pump Inhibitors: A Comprehensive Review.Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatmentSystematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.Review article: treatment for gastro-oesophageal reflux disease--lifestyle advice and medication.Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitudeRabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitisPharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pyloriProton Pump Inhibitors: More Indigestion than Relief?Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation.Formulation and evaluation of sustained release matrix tablet of rabeprazole using wet granulation technique.Proton pump inhibitor-induced hypomagnesemia: A new challenge.Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
P2860
Q27005916-45F62C53-4CCA-4425-9D35-DBF7A81D3185Q28070003-056A825A-BAEC-4B65-9E7A-94CD69DE5917Q33739015-78C22031-A39E-4D6D-9D38-5234CE575EFFQ35086840-7F65107B-F184-4CB9-A6F1-4A82858F05FCQ35827487-27A2A6FB-2937-40D3-80E1-53CEDD83E009Q35923949-1AD70D3A-388F-4CE2-96E7-0817CDBBC42BQ35923959-38C14C6B-469B-4174-8933-ED580D7C6D3BQ35923964-5C35EDCF-EBC9-4F3E-BC94-2B2F8CCEA11DQ35970047-A99894A5-8F3C-441E-AA76-EA5D171D46FFQ36308910-AFF497E8-E47E-4CB8-A18C-921F8F965037Q36322095-A19A4F02-FE39-48ED-878A-FD52999B2B22Q37122451-91CCB3ED-E5AE-4A05-9DFB-79E0F6698C9CQ37201668-23D5B643-2CA4-4712-819E-29CDDFA6146EQ39152043-CFE0DA86-2256-45D4-AB10-F4676822703FQ39386649-2EF04143-1C56-45AC-9E5F-07EE19DAA943Q42115464-7BAE5995-C70C-42C2-A5A8-4E732BA82C59Q42735733-670876AE-D1AE-48E6-9112-D85F510FD3D0Q42969618-A02CA13C-824E-444E-A9E4-219F607E18EAQ43817657-84692773-ED16-4290-A2CB-A12FE0D4C607Q43944835-5581011C-D159-4262-B342-F994359F699DQ44066559-B2D74FD8-C084-428D-8606-53314FA12717Q44297038-718B467C-245A-4A00-9E93-F355FB419630Q44352717-9D0AA49A-3762-4E8C-A12E-D09FEEFC98C0Q44505171-F3391FC2-DE51-45BE-9235-99794D9B0134Q44611988-8B9901EE-AA8E-4B67-9F6F-FDAA8E9A987F
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Review article: the pharmacology of rabeprazole.
@ast
Review article: the pharmacology of rabeprazole.
@en
type
label
Review article: the pharmacology of rabeprazole.
@ast
Review article: the pharmacology of rabeprazole.
@en
prefLabel
Review article: the pharmacology of rabeprazole.
@ast
Review article: the pharmacology of rabeprazole.
@en
P2860
P1476
Review article: the pharmacology of rabeprazole.
@en
P2093
M P Williams
R E Pounder
P2860
P356
10.1046/J.1365-2036.1999.00019.X
P407
P478
13 Suppl 3
P50
P577
1999-08-01T00:00:00Z